Jennifer R. Brown, MD, PhD, on ALPINE Data, CLL Highlights at ASH 2022
By Jennifer R. Brown, MD, PhD - Last Updated: February 8, 2024Blood Cancers Today caught up with the Society of Hematologic Oncology President Jennifer R. Brown, MD, PhD, to find out what she was watching at the 64th American Society of Hematology Annual Meeting. Dr. Brown highlighted data from the phase III ALPINE study, which compared zanubrutinib with ibrutinib as a treatment for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Advertisement
Post Tags:ASH22
Advertisement
Related Posts
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.